Surprisingly, the US Food and Drug Administration has declined to approve rimonabant, primarily due to its slight potential to enhance anxiety and suicidal thoughts. The atmosphere of consternation of possible legal action due to side effects may have led to this decision. The other side of the same coin is anorexia. While in obese populations weight loss is the main goal, in other populations, Inhibitors,research,lifescience,medical such as patients with cancer or AIDS, it is an immense problem. Dronabinol (synthetic THC, known
as Marinol and approved for the treatment of nausea and vomiting in cancer and AIDS patients) is associated with consistent improvement in appetite.69 It was found to be safe and effective for anorexia associated with weight loss in patients with AIDS, and is associated with increased appetite, improvement in mood, and decreased
nausea. In clinical trials, weight was stable in dronabinol patients, while placebo recipients lost weight.70,71 Dronabinol was found to be safe and effective for treatment of HIV wasting syndrome,72 Inhibitors,research,lifescience,medical as well as in patients with Alzheimer’s disease73 and with advanced cancer,73,74 The possible mechanisms of these actions have been reviewed.75 Cannabinoids have a positive effect in controlling chemotherapy-related sickness.76 They are more effective Inhibitors,research,lifescience,medical buy Tasocitinib antiemetics than the dopamine receptor antagonists such as chlorpromazinetype Inhibitors,research,lifescience,medical drugs.77 Direct comparisons with serotonin (5-HT)3 antagonists, which are widely used as antiemetics, have not been reported. However, while these antagonists are not effective in delayed vomiting, THC is known to reduce this side effect of chemotherapy. Pain Cannabis has been used for millennia as a pain-relieving substance. Evidence suggests that cannabinoids may prove useful in pain modulation by inhibiting neuronal Inhibitors,research,lifescience,medical transmission in pain pathways. Considering the pronounced antinociceptive effects produced by cannabinoids,
they were proposed to be a promising therapeutic approach for the clinical management of trigeminal neuralgia.78 THC, CBD, and CBD-dimethyl heptyl (DMH) were found to block the release of serotonin from platelets induced by plasma obtained from the patients during migraine attack.79 However, in other reports cannabinoids are much less successful in pain-relieving. Mephenoxalone In a clinical trial THC did not have any significant effect on ongoing and paroxysmal pain, allodynia, quality of life, anxiety/depression scores and functional impact of pain. These results do not support an overall benefit of THC in pain and quality of life in patients with refractory neuropathic pain.80 Similarly, in an additional clinical trial, no evidence was found81 of analgesic effect of orally administered THC in postoperative pain in humans. Other studies show much better results of pain relief.